Asthma Therapeutics in Asia-Pacific Markets to 2023 - High Prevalence and Highly Priced Existing & Upcoming Biologics will Drive the Market

  • ID: 4318622
  • Report
  • Region: Asia Pacific
  • 134 Pages
  • GBI Research
1 of 5
Asia-Pacific Asthma Therapeutics Market is Forecast to Grow Significantly over the Forecast Period, from $4.1 Billion in 2016 to a Projected Value of $6 Billion by 2023, at a CAGR of 5.4%

FEATURED COMPANIES

  • Astellas Pharma
  • AstraZeneca
  • Boehringer Ingelheim
  • Genentech
  • GlaxoSmithKline
  • Merck & Co
  • MORE

Summary

Asthma is a common chronic inflammatory disease of the airways. It is characterized by recurrent attacks of breathlessness and wheezing that vary in frequency and severity from patient to patient. Variable degrees of airflow obstruction, bronchial hyper-responsiveness and underlying inflammation determine the severity of the disease in each patient. The exact nature of the underlying inflammation reflects different aspects of the disease, such as its persistence or intermittency, and whether symptoms are chronic or acute (NHLBI, 2007). The inflammatory response and disease progression underlying asthma is mediated by various types of inflammatory cells and other cellular elements, which may include mast cells, neutrophils, eosinophils, lymphocytes and macrophages

Asthma treatment can be classed as either long-term control medication, aimed at controlling persistent asthma, or quick-relief medication, for the relief of exacerbations and acute symptoms. Long-term control medication includes inhaled corticosteroids (ICS), immunomodulators, leukotriene modifiers, cromolyn sodium, nedocromil and methylxanthines. In addition, long-acting beta-adrenoceptor agonists (LABA) can be used in combination with ICSs but not as monotherapies for moderate or severe persistent asthma. Currently, only two biologics Xolair (omalizumab) and Nucala (mepolizumab) are approved as add-on therapy for the treatment of allergic and severe refractory eosinophilic asthma in the Asia-Pacific region.

Asia-Pacific asthma therapeutics market is forecast to grow significantly over the forecast period, from $4.1 billion in 2016 to a projected value of $6 billion by 2023, at a compound annual growth rate (CAGR) of 5.4%.

The aging population is growing significantly, which will increase the asthma prevalence in the Asia-Pacific region. In addition, the severity of asthma increases with age, meaning elderly patients require more medications to control their asthma symptoms, which will drive the market (Kopnina, 2012). The prevalence rate of asthma in the Asia-Pacific region in the elderly population is 1.3-15.3%, compared with 5% in the adult population (Song et al., 2014).

The late-stage pipeline contains promising targeted therapies that have the potential for approval and launch during the forecast period. There are four costly biologics that are set to enter the Asia-Pacific asthma therapeutics market: Teva’s reslizumab, Sanofi/Regeneron’s dupilumab, and AstraZeneca’s tralokinumab and benralizumab.

China has a lack of biologic development, despite having the second highest asthma prevalence population after India. In addition, the only approved biologic Xolair (omalizumab) is yet to be approved in China, and although it has been available in India since before 2009, its market uptake there is negligible. These findings clearly indicate that there is a significant drug affordability barrier in India and China.

The report "Asthma Therapeutics in Asia-Pacific Markets to 2023 High Prevalence and Highly Priced Existing & Upcoming Biologics will Drive the Market" provides an introduction to asthma, detailing the epidemiology, etiology, diagnostic techniques, pathophysiology and prognosis for patients. An analysis of current treatment algorithms and options is also included.

In depth, this report provides the following:

  • Provides detailed analysis of the drugs currently marketed for asthma: Arnuity, Seretide/Adoair, Symbicort, Relvar/Breo, Flutiform, Xolair, Montelukast sodium, Spiriva and Nucala. This includes key characteristics, covering safety and efficacy, clinical trial outcomes, tolerability, dosing, administration, prices and overall competitive strength. These products are also compared in a comprehensive heat map.
  • Provides detailed analysis of the pipeline for asthma, by stage of development, molecule type, program type, mechanism of action and molecular target.
  • Provides detailed analysis of recent clinical trials in this indication by enrollment, duration and failure rate. Finally, promising late-stage pipeline molecules are analyzed and assessed in terms of their potential competitive strength.
  • Supplies forecasts for the asthma market for the 2016-2023 period, including epidemiology, treatment usage patterns, pricing and market size. The five Asia-Pacific markets are covered, and data are presented at a country level.
  • Provides detailed analysis of key market drivers and barriers for the asthma market.

Scope

The current asthma market in the Asia-Pacific region contains novel products, including Xolair, a recombinant humanized monoclonal anti-IgE antibody; Seretide/Adoair, an ICS-LABA combination therapy; Relvar/Breo, another ICS-LABA combination therapy; and Spiriva, a LAMA.

  • What are the competitive advantages of the existing novel drugs?

With over 290 active pipeline molecules, most of the late-stage investigational drug candidates offer improved dosing regimens and administration routes in comparison to currently marketed products.

  • Which classes of novel drugs are most prominent within the pipeline?
  • How much potential is there for the pipeline to address unmet needs within the asthma market?

Analysis of clinical trials since 2006 has identified that the failure rates of asthma molecules were highest in Phase III (60%).

  • How do failure rates vary by product stage of development, molecule type, and mechanism of action?
  • How do other factors, such as average trial duration and trial size influence the costs and risks associated with product development?

Over the 2016-2023 forecast period the asthma therapeutics market in the Asia-Pacific region is expected to increase in value at a compound annual growth rate of 5.4%, from $4.1 billion to over $6 billion.

  • Which markets make the most significant contribution to the current market size?
  • What are the epidemiology trends in these markets?
  • Will new market entrants lead to substantial changes in annual therapy costs?
  • How will different treatment usage patterns impact growth in the five assessed Asia-Pacific markets?

Reasons to buy

  • Understand the clinical context of asthma by considering symptoms, etiology, pathophysiology, epidemiology, diagnosis, and treatment options.
  • Identify the therapeutic strategies, products, and companies that dominate the current marketed products landscape, and recognize gaps and areas of unmet need.
  • Identify key pipeline trends in molecule type, administration route, mechanism of action and novelty. Analyze the asthma pipeline and stratify pipeline therapies by stage of development, molecule type and molecular target. There are signs in the pipeline that the industry is seeking novel approaches to meet unmet needs within asthma.
  • Consider market opportunities and potential risks by examining trends in asthma clinical trial size, duration, and failure rate by stage of development, molecule type, and mechanism of action.
  • Recognize the late-stage pipeline molecules that have demonstrated strong therapeutic potential in asthma by examining clinical trial data and multi-scenario product forecast projections.
  • Compare treatment usage patterns, annual therapy costs, and market growth projections for China, India, Australia, South Korea and Japan.
  • Discover trends in licensing and co-development deals concerning asthma products and identify the major strategic consolidations that have shaped the commercial landscape.
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Astellas Pharma
  • AstraZeneca
  • Boehringer Ingelheim
  • Genentech
  • GlaxoSmithKline
  • Merck & Co
  • MORE

1 Table of Contents

2 Introduction
2.1 Disease Introduction
2.2 Epidemiology
2.3 Symptoms
2.4 Etiology and Pathophysiology
2.4.1 Pathophysiology
2.5 Diagnosis
2.6 Disease Stages
2.7 Prognosis
2.8 Treatment Guidelines and Options
2.8.1 Treatment Algorithm
2.8.2 Pharmacological Treatments
2.8.3 Non-Pharmacological Treatments

3 Marketed Products
3.1 Overview
3.2 ICS for the Maintenance Treatment of Asthma
3.2.1 Arnuity (fluticasone furoate) - GlaxoSmithKline
3.3 ICS-LABA Combination Therapy for the Maintenance Treatment of Asthma
3.3.1 Seretide/Adoair (fluticasone propionate and salmeterol xinafoate) - GlaxoSmithKline
3.3.2 Symbicort (budesonide and formoterol fumarate) - AstraZeneca, Co-promotion with Astellas Pharma
3.3.3 Relvar/Breo (vilanterol trifenatate and fluticasone furoate) - GlaxoSmithKline
3.3.4 Flutiform (fluticasone propionate and formoterol fumarate) - SkyePharma
3.4 Add-on Therapy to ICS or ICS-LABA Therapies for the Maintenance Treatment of Asthma
3.4.1 Xolair (omalizumab) - Novartis and Genentech
3.4.2 Montelukast Sodium - Merck & Co
3.4.3 Spiriva (tiotropium bromide) - Boehringer Ingelheim
3.4.4 Nucala (mepolizumab) - GlaxoSmithKline
3.5 Comparative Efficacy and Safety of Marketed Products

4 Pipeline Analysis
4.1 Overview
4.2 Pipeline by Stage of Development, Molecule Type, Route of Administration and Program Type
4.3 Pipeline by Molecular Target
4.4 Promising Pipeline Molecules
4.4.1 Reslizumab - Teva Pharmaceutical
4.4.2 Dupilumab - Regeneron/Sanofi
4.4.3 Tralokinumab - AstraZeneca
4.4.4 Benralizumab - AstraZeneca
4.4.5 Fevipiprant - Novartis
4.5 Comparative Efficacy and Safety of Pipeline Products
4.6 Product Competitiveness Framework

5 Clinical Trial Analysis
5.1 Failure Rate
5.1.1 Overall Failure Rate
5.1.2 Failure Rate by Phase and Molecule Type
5.1.3 Failure Rate by Phase and Molecular Target
5.2 Clinical Trial Duration
5.2.1 Clinical Trial Duration by Molecule Type
5.2.2 Clinical Trial Duration by Molecular Target
5.3 Clinical Trial Size
5.3.1 Patient Enrollment per Trial by Molecule Type, Molecular Target and Stage of Development
5.3.2 Patient Enrollment per Product by Molecule Type, Molecular Target and Stage of Development
5.4 Summary of Clinical Trial Metrics

6 Multi-Scenario Forecast
6.1 Geographical Markets
6.2 Asia-Pacific Market
6.3 India
6.3.1 Treatment Usage Patterns
6.3.2 Annual Cost of Therapy
6.3.3 Market Size
6.4 China
6.4.1 Treatment Usage Patterns
6.4.2 Annual Cost of Therapy
6.4.3 Market Size
6.5 Australia
6.5.1 Treatment Usage Patterns
6.5.2 Annual Cost of Therapy
6.5.3 Market Size
6.6 South Korea
6.6.1 Treatment Usage Patterns
6.6.2 Annual Cost of Therapy
6.6.3 Market Size
6.7 Japan
6.7.1 Treatment Usage Patterns
6.7.2 Annual Cost of Therapy
6.7.3 Market Size

7 Drivers and Barriers
7.1 Drivers
7.1.1 Rising Aging Population and Asthma Risk Factors
7.1.2 Promising Product Pipeline and Launch of First-in-Class Molecules
7.1.3 New Costly Market Entries
7.1.4 Diversified Healthcare Reform to Boost Market Growth
7.2 Barriers
7.2.1 Sales Erosion by Generics
7.2.2 Competition from Traditional Medicines
7.2.3 Treatment Regimen Adherence
7.2.4 Limited Understanding of Underlying Causes
7.2.5 Lack of Awareness and Affordability of High-Cost Biological Products

8 Deals and Strategic Consolidations
8.1 Licensing Deals
8.1.1 Deals by Region and Value
8.1.2 Number of Disclosed and Undisclosed Deals by Year, Aggregate Deal Value
8.1.3 Deal Value by Stage of Development, Molecule Type and Molecular Target
8.1.4 Key Licensing Deals
8.2 Co-development Deals
8.2.1 Deals by Region and Value
8.2.2 Number of Disclosed and Undisclosed Deals by Year, Aggregate Deal Value
8.2.3 Deal Value by Stage of Development, Molecule Type and Molecular Target
8.2.4 Key Co-development Deals

9 Appendix
9.1 All Pipeline Drugs by Phase of Development
9.1.1 Discovery
9.1.2 Preclinical
9.1.3 Investigational New Drug/ Clinical Trial Authorization-Filed
9.1.4 Phase I
9.1.5 Phase II
9.1.6 Phase III
9.1.7 Pre-registration
9.2 Summary of Multi-Scenario Market Forecasts to 2023
9.2.1 Asia-Pacific
9.2.2 China
9.2.3 India
9.2.4 Australia
9.2.5 South Korea
9.2.6 Japan
9.3 References
9.4 Abbreviations
9.5 Research Methodology
9.5.1 Secondary Research
9.5.2 Marketed Product Profiles
9.5.3 Late-Stage Pipeline Candidates
9.5.4 Comparative Efficacy and Safety Heat Map for Marketed and Pipeline Products
9.5.5 Product Competitiveness Framework
9.5.6 Pipeline Analysis
9.5.7 Forecasting Model
9.5.8 Deals Data Analysis

List of Tables
Table 1: Asthma Therapeutics Market, Global, Classification of Asthma Severity in Children Aged 0-4
Table 2: Asthma Therapeutics Market, Global, Classification of Asthma Severity in Children Aged 5-11
Table 3: Asthma Therapeutics Market, Global, Classification of Asthma Severity in Those Aged 12 and over
Table 4: Asthma Therapeutics Market, Global, Classification of Asthma Severity According to GINA Guidelines (2002)
Table 5: Asthma Therapeutics, Global, Management of Chronic Asthma in Adults and Children Older than Five
Table 6: Asthma Diagnosis, Global, Symptoms and Management of Acute Asthma
Table 7: Asthma Trials, Global,Clinical Trial Endpoints
Table 8: Asthma Therapeutics Market, Global, Licensing Deals Valued Above $10m, 2006-2016
Table 9: Asthma Therapeutics Market, Global, Co-development Deals Valued Above $10m, 2006-2016
Table 10: Asthma Therapeutics Market, Global, All Pipeline Products, Discovery, 2016
Table 11: Asthma Therapeutics Market, Global, All Pipeline Products, Preclinical, 2016
Table 12: Asthma Therapeutics, Global, All Pipeline Products, IND/CTA-Filed, 2016
Table 13: Asthma Therapeutics Market, Global, All Pipeline Products, Phase I, 2016
Table 14: Asthma Therapeutics Market, Global, All Pipeline Products, Phase II, 2016
Table 15: Asthma Therapeutics Market, Global, All Pipeline Products, Phase III, 2016
Table 16: Asthma Therapeutics Market, Global, All Pipeline Products, Pre-registration, 2016
Table 17: Asthma Therapeutics Market, Asia-Pacific, Market Forecast, 2016-2023
Table 18: Asthma Therapeutics Market, China, Market Forecast, 2016-2023
Table 19: Asthma Therapeutics Market, India, Market Forecast, 2016-2023
Table 20: Asthma Therapeutics Market, Australia, Market Forecast, 2016-2023
Table 21: Asthma Therapeutics Market, South Korea, Market Forecast, 2016-2023
Table 22: Asthma Therapeutics Market, Japan, Market Forecast, 2016-2023

List of Figures
Figure 1: Asthma Therapeutics Market, Comparative Efficacy and Safety Heatmap for Marketed Products
Figure 2: Asthma Therapeutics Market, Global, Pipeline, 2016
Figure 3: Asthma Therapeutics Market, Global, Pipeline by Molecular Target, 2016
Figure 4: Asthma Therapeutics Market, Global, Pipeline by Molecular Target and Stage of Development, 2016
Figure 5: Asthma Therapeutics Market, Asia-Pacific, Reslizumab Forecast ($m), 2017-2023
Figure 6: Asthma Therapeutics Market, Asia-Pacific, Dupilumab Forecast ($m), 2019-2023
Figure 7: Asthma Therapeutics Market, Asia-Pacific, Tralokinumab Forecast ($m), 2019-2023
Figure 8: Asthma Therapeutics Market, Asia-Pacific, Benralizumab Forecast ($m), 2018-2023
Figure 9: Asthma Therapeutics Market, Asia-Pacific, Fevipiprant Forecast ($m), 2021-2023
Figure 10: Asthma Therapeutics Market, Comparative Efficacy and Safety Heatmap for Pipeline Products
Figure 11: Asthma Therapeutics Market, Competitor Matrix for Asthma Marketed and Pipeline Products, 2016
Figure 12: Asthma Therapeutics, Global, Average Clinical Trial Failure Rate (%), 2006-2016
Figure 13: Asthma Therapeutics, Global, Clinical Trial Failure Rate by Molecule Type, 2006-2016
Figure 14: Asthma Therapeutics, Global, Clinical Trial Failure Rate by Molecular Target, 2006-2016
Figure 15: Asthma Therapeutics, Global, Clinical Trial Duration by Phase and Molecule Type, 2006-2016
Figure 16: Asthma Therapeutics, Global, Clinical Trial Duration by Phase and Molecular Target, 2006-2016
Figure 17: Asthma Therapeutics, Global, Clinical Trial Size per Individual Trial by Stage of Development and Molecule Type, 2006-2016
Figure 18: Asthma Therapeutics, Global, Clinical Trial Size per Individual Trial by Stage of Development and Molecular Target, 2006-2016
Figure 19: Asthma Therapeutics, Global, Clinical Trial Size per Product by Stage of Development and Molecule Type, 2006-2016
Figure 20: Asthma Therapeutics, Global, Clinical Trial Size per Product by Stage of Development and Molecular Target, 2006-2016
Figure 21: Asthma Therapeutics Market, Global, Comparison of Average Trial Metrics by Phase and Molecule Type
Figure 22: Asthma Therapeutics Market, Global, Comparison of Average Trial Metrics by Phase and Molecular Target
Figure 23: Asthma Therapeutics Market, Asia-Pacific, Treatment Patterns, 2016-2023
Figure 24: Asthma Therapeutics Market, Asia-Pacific, Market Size ($bn), 2016-2023
Figure 25: Asthma Therapeutics Market, India, Treatment Usage Patterns (million), 2016-2023
Figure 26: Asthma Therapeutics Market, India, Annual Cost of Therapy ($), 2016-2023
Figure 27: Asthma Therapeutics Market, India, Market Size ($m), 2016-2023
Figure 28: Asthma Therapeutics Market, China, Treatment Usage Patterns, 2016-2023
Figure 29: Asthma Therapeutics Market, China, Annual Cost of Therapy ($), 2016-2023
Figure 30: Asthma Therapeutics Market, China, Market Size ($m), 2016-2023
Figure 31: Asthma Therapeutics Market, Australia, Treatment Usage Patterns (million), 2016-2023
Figure 32: Asthma Therapeutics Market, Australia, Annual Cost of Therapy ($), 2016-2023
Figure 33: Asthma Therapeutics Market, Australia, Market Size ($m), 2016-2023
Figure 34: Asthma Therapeutics Market, South Korea, Treatment Usage Patterns (million), 2016-2023
Figure 35: Asthma Therapeutics Market, South Korea, Annual Cost of Therapy ($), 2016-2023
Figure 36: Asthma Therapeutics Market, South Korea, Market Size ($m), 2016-2023
Figure 37: Asthma Therapeutics Market, Japan, Treatment Usage Patterns (million), 2016-2023
Figure 38: Asthma Therapeutics Market, Japan, Annual Cost of Therapy ($), 2016-2023
Figure 39: Asthma Therapeutics Market, Japan, Market Size ($m), 2016-2023
Figure 40: Asthma Therapeutics Market, Global, Licensing Deals by Region and Value, 2006-2016
Figure 41: Asthma Therapeutics Market, Global, Number of Disclosed and Undisclosed Licensing Deals by Year, Aggregate Deal Value ($m) and Aggregate Upfront Value ($m), 2006-2016
Figure 42: Asthma Therapeutics Market, Global, Licensing Deals by Stage of Development, Deal Value ($m) and Upfront Payment Value ($m), 2006-2016
Figure 43: Asthma Therapeutics Market, Global, Licensing Deals by Molecule Type, Stage of Development and Aggregate Deal Value ($m), 2006-2016
Figure 44: Asthma Therapeutics Market, Global, Licensing Deals by Molecular Target, Aggregate Deal Value ($m) and Aggregate Upfront Payment Value ($m), 2006-2016
Figure 45: Asthma Therapeutics Market, Global, Co-development Deals by Region, 2006-2016
Figure 46: Asthma Therapeutics Market, Global, Number of Disclosed and Undisclosed Co-development Deals by Year, Aggregate Deal Value ($m) and Aggregate Upfront Value ($m), 2006-2016
Figure 47: Asthma Therapeutics Market, Global, Co-development Deals by Stage of Development, Deal Value ($m) and Upfront Payment Value ($m), 2006-2016
Figure 48: Asthma Therapeutics Market, Global, Co-development Deals by Molecule Type, Stage of Development and Aggregate Deal Value ($m), 2006-2016
Figure 49: Asthma Therapeutics Market, Global, Co-development Deals by Molecular Target, Aggregate Deal Value ($m) and Aggregate Upfront Payment Value ($m), 2006-2016

Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • Astellas Pharma
  • AstraZeneca
  • Boehringer Ingelheim
  • Genentech
  • GlaxoSmithKline
  • Merck & Co
  • Novartis
  • Regeneron/Sanofi
  • SkyePharma
  • Teva Pharmaceutical
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll